

FORM PTO-1390
(REV 10-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

P/717-189

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/787335

INTERNATIONAL APPLICATION NO.
PCT/EP99/06844

INTERNATIONAL FILING DATE
16 September 1999

PRIORITY DATE CLAIMED
18 September 1998

TITLE OF INVENTION
CHEMOKINE RECEPTOR ANTAGONIST AND CYCLOSPORIN IN COMBINED THERAPY

APPLICANT(S) FOR DO/EO/US
Hermann-Joseph GRONE et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). - **unsigned**
10. ☒ **XXXXXXXXXXXXXXXXXXXX** An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
2 sheets of drawings
Print EFS form.

EXPRESS MAIL CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addresses (mail label)
EL583744475US in an envelope addressed to:
Asst. Commissioner for Patents, Washington, D.C. 20231,
on **March 16, 2001**.


Dorothy Jenkins

Name of Person Mailing Correspondence

Dorothy Jenkins
Signature

March 16, 2001

Date of Signature

U.S. APPLICATION NO. (if known) 09/787335		INTERNATIONAL APPLICATION NO. PCT/EP99/06844		ATTORNEY'S DOCKET NUMBER P/717-189	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =	0	X \$18.00	\$	
Independent claims	3 - 3 =	0	X \$80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			0	+ \$270.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 860.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$ 860.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 860.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$ 860.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>860.</u> to cover the above fees is enclosed. Check No. 3826					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>15-0700</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: OSTROLENK, FABER, GERB & SOFFEN, LLP 1180 Avenue of the Americas New York, NY 10036-8403 Tel: (212) 382 0700					
				 SIGNATURE: Edward A. Meilman NAME 24,735 REGISTRATION NUMBER	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Hermann-Joseph GRONE et al

Date: March 16, 2001

Serial No.:

Group Art Unit:

Filed:

Examiner:

For: CHEMOKINE RECEPTOR ANTAGONIST AND CYCLOSPORIN IN COMBINED
THERAPY

Asst. Commissioner for Patents

Washington, D.C. 20231

AMENDMENT/SUBMISSION

Prior to examination, please amend the application as follows.

FEE CALCULATION

Any additional fee required has been calculated as follows:

_____ If checked, "Small Entity" status is claimed.

	NO. CLAIMS		HIGHEST NO.						ADDIT.
	AFTER		PREVIOUSLY						FEE
	AMENDMENT		PAID FOR		EXTRA PRESENT		RATE		
TOTAL	16	MINUS	20	* =	0	X	(\$9 SE or \$18)		\$
INDEP.	3	MINUS	3	** =	0	X	(\$40 SE or \$80)		\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM						X	(\$135 SE or \$270)		\$

* not less than 20 ** not less than 3

TOTAL \$ -----

If any additional payment is required, a check which includes the calculated fee of \$_____ (OFGS Check No. _____) is attached.

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. §1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

AMENDMENTS

 X If checked, amendment(s) to the specification and/or claims are submitted herewith.

1. If checked, an abstract is submitted as the last page of Appendix A.

3. Claims:

Please amend claims 3-8 and 11-16 pursuant to 37 C.F.R. § 1.121(c)(i) as set forth in the “clean” version attached hereto as Appendix A. Entry is respectfully requested. A version with markings to show the changes made pursuant to 37 C.F.R. § 1.121(c)(ii) is attached hereto as Appendix B.

 If checked, the optional complete set of “clean” claims pursuant to 37 C.F.R. § 1.121(c)(3) is attached hereto as Appendix C.

09/787335

REMARKS/ARGUMENT

JC12 Rec'd PCT/PTO 16 MAR 2001

This Preliminary Amendment is submitted to change the multiple dependent claims to single dependent claims in order to reduce the government filing fee.

EXPRESS MAIL CERTIFICATE

Respectfully submitted,

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail to Addressee (mail label # EL583744475US) in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231, on March 16, 2001:

Dorothy Jenkins

Name of Person Mailing Correspondence

Dorothy Jenkins
Signature

March 16, 2001

Date of Signature

Edward A. Meilman

Edward A. Meilman

Registration No.: 24,735

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700

APPENDIX A
“CLEAN” VERSION OF EACH PARAGRAPH/SECTION/CLAIM
37 C.F.R. § 1.121(b)(ii) AND (c)(i)

CLAIMS (with indication of amended or new):

(Amended) 3. The use according to claim 1, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

(Amended) 4. The use according to claim 1, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

(Amended) 5. The use according to claim 1, wherein the chemokine receptor antagonist is Met-RANTES.

(Amended) 6. The use according to claim 1, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

(Amended) 7. The use according to claim 1, wherein the cyclosporin is cyclosporin A.

(Amended) 8. The use according to claim 1, for treating or preventing renal allograft transplantation.

(Amended) 11. The pharmaceutical composition according to claim 9, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

(Amended) 12. The pharmaceutical composition according to claim 9, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

(Amended) 13. The pharmaceutical composition according to claim 9, wherein the chemokine receptor antagonist is Met-RANTES.

(Amended) 14. The pharmaceutical composition according to claim 9, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

(Amended) 15. The pharmaceutical composition according to claim 10, wherein the cyclosporin is cyclosporin A.

(Amended) 16. The pharmaceutical composition according to claim 9, for treating or preventing renal allograft transplantation.

00500047 1

APPENDIX B

VERSION WITH MARKINGS TO SHOW CHANGES MADE

37 C.F.R. § 1.121(b)(iii) AND (c)(ii)

CLAIMS:

3. The use according to [any preceding claim] claim 1, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.
4. The use according to [claims 1 or 2] claim 1, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.
5. The use according to [claims 1 or 2] claim 1, wherein the chemokine receptor antagonist is Met-RANTES.
6. The use according to [any preceding claim] claim 1, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.
7. The use according to [any preceding claim] claim 1, wherein the cyclosporin is cyclosporin A.
8. The use according to [any preceding claim] claim 1, for treating or preventing renal allograft transplantation.
11. The pharmaceutical composition according to [claim 9 or 10] claim 9, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.
12. The pharmaceutical composition according to [claims 9 or 10] claim 9, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.
13. The pharmaceutical composition according to [claims 9 or 10] claim 9, wherein the chemokine receptor antagonist is Met-RANTES.

14. The pharmaceutical composition according to [any of claims 9 to 13] claim 9, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

15. The pharmaceutical composition according to [any of claims 10 to 14] claim 10, wherein the cyclosporin is cyclosporin A.

16. The pharmaceutical composition according to [any of claims 9 to 15] claim 9, for treating or preventing renal allograft transplantation.

00500047 1

2/PRTS

09/787335

532 Rec'd PCT/PTO 16 MAR 2001

WO 00/16796

PCT/EP99/06844

CHEMOKINE RECEPTOR ANTAGONIST AND CYCLOSPORIN IN COMBINED
THERAPY

FIELD OF THE INVENTION

5 The present invention relates to the use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells. It also relates to said pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified therapy.

10 In particular, it relates to the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection.

BACKGROUND OF THE INVENTION

15 The mechanisms by which a T cell response to a foreign (allogeneic or xenogeneic) protein or cell or organ is mounted are fairly well understood. Antigen presenting cells (APCs) are attracted to areas of inflammation or damage (that may be induced by surgical transplantation). The repertoire of T cells in the periphery is constantly surveying tissues for evidence of pathogens or the presence of foreign (allo- or xenogeneic) tissue. Once any of
20 these warning signals are recognised, the APCs engulf the protein, digest it and present it to the host's immune system.

 The immune system is well equipped to rapidly identify foreign, diseased or inflamed tissue and rapidly destroys it. This has always been a major barrier to tissue, organ and cell transplantation as well as gene therapy. Major problems are generally associated with
25 chronic immunosuppression, encapsulation or immunoisolation. The unwanted side effects of chronic immunosuppression include increased susceptibility to opportunistic infection and tumour formation.

 In particular, acute renal allograft rejection is mediated by both alloantigen-dependent and -independent factors and is characterised by a mononuclear cell infiltrate

00787335-051301

consisting mainly of T lymphocytes, monocyte/macrophages and occasional eosinophils (Gröne H.J., 1996, Valente J.F. et al., 1998, Bishop G.A. et al., 1986). The recruitment of these leukocytes from the peripheral circulation into the transplanted organ involves a complex interplay between a series of molecules expressed on the leukocyte and endothelial surface (Butcher E.C., 1991, Butcher E.C. et al., 1996, Springer T.A., 1994).

The desire for long-term acceptance of grafted tissue in the absence of continuous immunosuppression is a long-standing goal in human medicine.

Chemokines, a large superfamily of structurally related cytokines, have been shown to selectively promote the rapid adhesion, chemotaxis and activation of specific leukocyte effector subpopulations (Springer T.A., 1994, Nelson P.J. et al., 1998, Luster A.D., 1998, Schlöndorff D. et al., 1997).

Chemokines are characterised by a series of shared structural elements including the conserved cysteine residues used to define the C, C-C, C-X-C and C-X₃-C chemokine subgroups (where X represents an intervening amino acid residue between the first two amino terminal proximal cysteines). All of the various biological actions of chemokines appear to be directed through their interaction with a large family of seven-transmembrane spanning, C-protein coupled receptors (Nelson P.J. et al., 1998, Luster A.D., 1998, Schlöndorff D. et al., 1997). The cell type specific expression of these receptors appears to control a significant degree, the leukocyte specificity of chemokine action (Nelson P.J. et al., 1998, Luster A.D., 1998, Schlöndorff D. et al., 1997).

The chemokine RANTES (regulated upon activation, normal T-cell expressed and secreted), a member of the C-C chemokine subfamily, is a ligand for a number of chemokine receptors including CCR1, CCR3, CCR5, CCR9 and DARC (Duffy Antigen Receptor for Chemokines) in humans (Nelson P.J. et al., 1998, Luster A.D., 1998, Schlöndorff D. et al., 1997, Nibbs R.J. et al., 1997). RANTES is a potent chemoattractant for T cells, monocytes, natural killer cells, basophils and eosinophils (Nelson P.J. et al., 1998).

Chemokines such as RANTES, are thought to play pivotal roles in the cellular infiltrates that underlie various disease processes. For example, RANTES is expressed *in vivo* in diseases characterised by a mononuclear cell infiltrate including, delayed-type

hypersensitivity, necrotizing glomerulonephritis, inflammatory lung disease and renal allograft rejection (Schlöndorff D. et al., 1997, Nelson P.J. et al., 1998, Devergne O. et al., 1994, Luckas N.W. et al., 1996, Lloyd C.M. et al., 1997, Pattison J. et al., 1994, Wiedermann C.J. et al., 1993). In studies of human kidneys undergoing acute cellular rejection, RANTES protein was found localised to mononuclear infiltrating cells, renal tubular epithelial cells and tile endothelium of peritubular capillaries (Pattison J. et al., 1994, Wiedermann C.J. et al., 1993). Since acute cellular rejection is characterised by an intravascular mad interstitial cellular infiltrate consisting of monocyte/macrophages, T lymphocytes and occasional eosinophils, RANTES is potentially a key player in the pathogenesis of acute rejection (Schlöndorff D. et al., 1997, Nelson P.J. et al., 1998, Pattison J. et al., 1994, Wiedermann C.J. et al., 1993).

Based upon these observations a model for the role of RANTES in renal allograft rejection was proposed (Nelson P.J. et al., 1998, Pattison J. et al., 1994, Wiedermann C.J. et al., 1993). Early in rejection, the microvascular endothelium becomes inflamed, platelets degranulate, releasing RANTES protein that binds to the endothelial surface. The inflamed renal tubules and endothelial cells produce additional chemokines including RANTES. The accumulated surface bound chemokines then provide directional signals to circulating leukocytes as they roll across the endothelial surface (Butcher E.C., 1991, Butcher E.C. et al., 1996, Springer T.A., 1994, Nelson P.J. et al., 1998, Pattison J. et al., 1994, Wiedermann C.J. et al., 1993). Leukocytes recognise the surface bound protein, upregulate integrins, and firmly adhere to the endothelial surface, undergo diapedesis and extravasation. As the leukocytes become activated, they produce additional cytokines and chemokines thus amplifying and propagating the inflammatory response (Nelson P.J. et al., 1998, Pattison J. et al., 1994, Wiedermann C.J. et al., 1993).

Modification of the amino terminus of the RANTES protein can dramatically alter its properties (Proudfoof A.E. et al., 1996, Gong J.H. et al., 1996, Simmons G. et al., 1997). The addition of a single methionine residue changes the agonist protein into a RANTES receptor antagonist with nanomolar potency (Proudfoof A.E. et al., 1996). This antagonist, Met-RANTES, is bioactive in mouse and rat (Proudfoot unpublished), and has been shown

to suppress inflammation in murine models of allergic skin and rheumatoid arthritis and to partially inhibit in necrotizing glomerulonephritis (Teixeira M.M et al., 1997, Plater-Zyberk C. et al., 1997, Lloyd C.M et al., 1997).

Cyclosporins represent a group of nonpolar cyclic oligopeptides, having immunosuppressant activity, produced by the fungus *Tolypocladium inflatum* Gams and other fungi imperfecti. The major component, cyclosporin A, has been identified along with several other minor metabolites, cyclosporins B through N. A number of synthetic analogues have also been prepared. Cyclosporin A is a commercially available drug, which has attained widespread clinical application as immunosuppressant in organ transplantation procedures.

The main problem with cyclosporin A has been its nephrotoxicity (Martindale, 1996), characterised by fluid retention, increased serum creatinine and urea concentrations, a fall in glomerular filtration rate, and decreased sodium and potassium excretion. In particular, in renal graft recipients may be difficult to distinguish nephrotoxicity from graft rejection.

DISCLOSURE OF THE INVENTION

We have now found that a combined treatment with a chemokine receptor antagonist and a low dose of a cyclosporin results in a reduction of the inflammatory events associated with transplant rejection, as compared to treatment with a cyclosporin alone.

In particular, we have found that Met-RANTES reduced damage to vasculues and tubules and caused a significant reduction of interstitial rejection in renal allograft transplantation.

Therefore, the main object of the present invention is the use of a chemokine receptor antagonist in combination with a cyclosporin to produce a pharmaceutical composition for treating or preventing the rejection of transplanted organs, tissues or cells. The chemokine receptor antagonist and the cyclosporin can be administered simultaneously, separately or sequentially.

Another object of the present invention is, therefore, the method for treating or preventing the rejection of transplanted organs, tissues or cells by administering

simultaneously, separately or sequentially an effective amount of a chemokine receptor antagonist and an effective amount of a cyclosporin, together with a pharmaceutically acceptable excipient.

5 An "effective amount" refers to an amount of the active ingredients that is sufficient to affect the course and the severity of the rejection of transplanted organs, tissues or cells, leading to the reduction or remission of such pathology. The effective amount will depend on the route of administration and the condition of the patient.

10 A further object of the present invention are the pharmaceutical compositions containing a chemokine receptor antagonist and a cyclosporin, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential administration of its active ingredients for treating or preventing the rejection of transplanted organs, tissues or cells.

15 In case of separate or sequential use of the two active ingredients, the pharmaceutical compositions of the invention will consist of two different formulations, each comprising one of the two active ingredients together with one or more pharmaceutically acceptable excipients.

20 "Pharmaceutically acceptable" is meant to encompass any carrier, which does not interfere with the effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which is administered. For example, for parenteral administration, the above active ingredients may be formulated in unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution.

Besides the pharmaceutically acceptable carrier, the compositions of the invention can also comprise minor amounts of additives, such as stabilisers, excipients, buffers and preservatives.

25 The administration of such active ingredients may be by intravenous, intramuscular or subcutaneous route. Other routes of administration, which may establish the desired blood levels of the respective ingredients, are comprised by the present invention.

The combined therapy of the present invention is suitable for treating or preventing the rejection of any transplanted organ, tissue or cell, but it is particularly advisable in cases of kidney transplantations, due to the nephrotoxicity of cyclosporin A.

5 The term "chemokine receptor antagonist" means any molecule, which acts as antagonist to the mature full-length naturally-occurring chemokines and, preferably, does not show significant chemoattractant activity. For the measurement of said chemoattractant activity reference is made for example to (Nelson P.J. et al., 1998).

10 The chemokine receptor antagonist is preferably selected among truncated RANTES molecules reported in International patent application WO 97/44462, truncated MCP-3, RANTES and MIP-1 α described in International patent application WO 98/06751, truncated RANTES and MCP-2 described in European patent application No. 97116863.8 or N-terminally extended RANTES described in WO 96/17935. Met-RANTES is particularly preferred. To the above-cited patent applications, reference is made also for the methods of preparation of the chemokine receptor antagonists mentioned.

15 The cyclosporin is selected among cyclosporin A, metabolites or synthetic analogues thereof. Preferably, it is cyclosporin A.

20 Therefore, a preferred embodiment of the invention consists in the combined use of Met-RANTES and cyclosporin A for treating or preventing the rejection of kidney allograft transplantation. In this case, the Applicant has found that it is possible to reduce the effective dose of cyclosporin and this is a great advantage considering the dose-dependent toxicity to the kidney which is known to be associated with the cyclosporin treatment.

The above effect has been showed with *in vivo* experiments on rats.

25 The invention will now be described by means of the following Examples, which should not be construed as in any way limiting the present invention. The Examples will refer to the Figures specified here below.

DESCRIPTION OF THE FIGURES

Figure 1: The ability of RANTES to bind directly to microvascular endothelium before and after 12 hours stimulation with IL-1 β (5 ng/ml) was determined. DMVEC was grown on 96 well plates and RANTES measured using a modified ELISA procedure.

- 5 Figure 2 a and b: The effects of Met-RANTES on firm arrest, spreading or transmigration of MonoMac 6 cells on activated microvascular endothelium under physiological flow. DMVEC grown to confluence in Petri dishes were stimulated with IL-1 β (5 ng/ml) or left untreated (control) for 12 hours, and pre-incubated with or without RANTES (10 ng/ml) for 30 minutes. MonoMac 6 cells were pre-treated with or without Met-RANTES (1 μ g/ml) for 10 30 minutes, and perfused at a constant flow rate of 1.5 dyn/cm². (a) Firm adhesion to DMVEC was determined by counting the number of firmly adherent monocytes in multiple fields after a 5 minutes period, and expressed as cells/mm². (b) Monocytes undergoing spreading or transmigration were counted after 5 minutes in multiple high power fields, and expressed as the percentage of initially firmly adherent cells. Data represent mean \pm SD of 3 15 independent experiments. (Note: the results were reproducible over a range of Met-RANTES from 0.01 to 1 μ g/ml).

EXAMPLES

Materials and methods

20 Cells used

- The monocytic tumour cell line MonoMac 6 was cultured in RPMI 1640 with 10% FCS supplemented as previously described (Ziegler-Heitbrock H.W.L. et al., 1988). The cells were routinely carried in 24-well plates (Costar) and the media and sera tested for low LPS content. Primary human dermal microvascular endothelial cell (DMVEC) from human 25 neonatal foreskin were obtained from Dr. K. Degitz (Dermatology, LMU, Munich, Germany). The cells were carried in MCDB 131 media (Gibco BRL, Eggenstein Germany) supplemented with 10% Fetal calf serum (Boehringer Mannheim, Germany), 1 mg/ml Hydrocortisone acetate (Sigma, Deisenhofen, Germany), 5×10^5 M Dibutyryl adenosine monophosphate (Sigma, Deisenhofen, Germany), 2 mM Glutamine

(Seromed, Berlin, Germany), 100U/ml Penicillin, 100 mg/ml Streptomycin, 25 mg/ml Amphotericin B (antibiotic/Antimycotic Sol. Gibco BRL, Eggenstein, Germany) and incubated at 37°C and 5% CO₂. The cells were grown on T75 flasks, 35 mm Petri plates (Costar, Corning, New York) or 96 well flat bottom plates (Nunc, Wiesbaden, Germany) precoated with 0.5% gelatine (Sigma, Deisenhofen, Germany). Medium was changed every 2-3 days. Cells were characterised, and purity of cultures was ensured through morphologic appearance and immunofluorescence flow cytometry for CD31 surface expression.

Materials

Materials for histologic studies were obtained from Merck (Darmstadt, Germany). Materials for chemical and immunologic measurements were supplied by Sigma (Munich, Germany). IL-1 β and TNF α were purchased from Sigma (Munich, Germany). Generation of recombinant RANTES and the RANTES specific monoclonal antibody VL1 were described previously (Von Luetlichau I., 1996). Met-RANTES was produced and endotoxin removed for *in vivo* studies as described previously (Proudfoof A.E. et al., 1996, Teixeira M.M et al., 1997, Plater-Zyberk C. et al., 1997, Lloyd C.M et al., 1997).

Animals and renal Transplantation

Inbred male rats were used in all experiments. Lewis (LEW, RT1^b) rats served as recipients of Fisher 344 (F344 RT1^{lv1}) or Brown Norway (BN RT1^{*}) kidneys. The animals were purchased from Charles River GmbH, Sulzfeld, Germany. The rats weighed 190 to 250 gm (Lew and F344) and 140 to 170 gm (BN) to adjust for ureter diameter. Transplantation was performed using a modification of the technique originally described by Fisher and Lee (Fisher B. et al., 1965). Briefly, the animals were anaesthetised by ether-drop anaesthesia, the donor kidney was flushed with 5 ml of cold 0.9% NaCl (4°C) with or without 100 μ g Met-RANTES. The kidney and ureter were removed en bloc including the renal artery with a 5-mm aortic cuff and the renal vein with a 3-mm vena cava patch. The kidneys were stored in 0.9% NaCl 4°C.

The donor kidney was transplanted to the abdominal aorta and inferior vena cava of the recipient animal, below the left renal artery, by end-to-side anastomoses with 8-0 nonabsorbable monofilament nylon suture. Ureter anastomosis was performed end-to-end

with 11-0 nonabsorbable monofilament nylon suture. Total ischemic time of the donor kidney varied between 30 and 40 min. Hyronephrosis was evaluated both macroscopically at time of death and by light microscopy. All animals with hyronephrosis were excluded from the experimental groups. The left kidney of the recipient was always removed at the time of transplantation. In the Fisher to Lewis transplantation the right kidney was left in place to have an internal control for the effects of Met-RANTES. In Brown Norway to Lewis transplantations a bilateral nephrectomy was performed at the time of transplantation.

Experimental Groups:

Experimental groups were as follows:

- 10 Group 1: Fisher 344 kidney into Lewis rat with one endogenous kidney.
 - Group 1a: with Met-RANTES 200 µg/day for 7 days (n=9)
 - Group 1b: without Met-RANTES for 7 days (n=9)
- Group 2: Brown Norway kidney into bilaterally nephrectomised Lewis rat with CyA 2.5 mg/kg BW administered per day.
- 15 Group 2a: with Met-RANTES, 50 µg/day for 12 days (n=4)
- Group 2b: without Met-RANTES for 12 days (n=4)

Cyclosporin A (CyA) (kindly provided by Sandoz, Basel, Switzerland) was dissolved in olive oil and administered subcutaneously in a concentration of 2.5 mg/kg BW per day for 12 days, starting 4 h post-transplantation. Met-RANTES was dissolved in water and adjusted to 0.9% sodium chloride and injected once daily intravenously at a dose of 200 µg per day in Fisher to Lewis and at a dose of 50 µg per day in Brown Norway to Lewis transplantation experiments.

Serum analysis

Blood taken from the aorta at the time of sacrifice was analysed for creatinine, urea, glucose, and bilirubin using an automated serum analyser. This did not provide information on renal function for the Fisher to Lewis model as the transplanted animals had one endogenous kidney, but these measurements were relevant in the Brown Norway to Lewis transplant model.

Histology

Organs (lung, liver, kidney, and spleen) were removed under deep anaesthesia. The organs were quickly blotted free of blood, weighed, and then processed as needed for histology, immunohistochemistry, or *in situ* hybridisation. The organs were cut into 1-mm slices and either immersion-fixed in 4% formaldehyde in phosphate buffered saline (PBS) pH 7.35, (PBS: 99 mM $\text{NaH}_2\text{PO}_4 \times \text{H}_2\text{O}$, 108 mM $\text{NaH}_2\text{PO}_4 \times 2\text{H}_2\text{O}$ and 248 mM NaCl) for 24 h or fixed in methacarn for 8 h and embedded in paraffin, or frozen in liquid nitrogen and consequently stored at -80°C until used for immunohistochemistry. Light microscopy was performed on 3 μm sections stained by periodic acid-Schiff or Goldner-Elastica.

Immunohistochemistry

10 The monoclonal antibody ED1 (Serotech/Camon, Wiesbaden, Germany) was used on methacarn fixed paraffin embedded tissue (3 μm) to demonstrate monocytes/macrophages. For detection for CD8 antigen expressed on cytotoxic T lymphocytes, monoclonal mouse antibodies were applied to frozen sections after ice cold acetone-fixation for 5 min (Serotech/Camon, Wiesbaden, Germany). An alkaline phosphatase anti-alkaline phosphatase detection system was applied (Dako, Hamburg, Germany). Controls, omitting the first or second antibody for each section tested, were negative.

Morphometry

20 Vascular injury score: Preglomerular vessels with endothelial damage, thrombus and endothelialitis were assessed as showing no injury (0), a mild (1), moderate (2) and severe (3) degree of injury and evaluated in whole kidney section including cortex, outer and inner medulla. A degree specific vascular injury index was defined as the percentage of vessels with the respective degree of injury encountered in a whole kidney section. Total vascular injury score was calculated as the sum of all vessels, with all degrees of vascular injury, whereby the number of vessels with degree one, was multiplied by one, that of degree two, by a factor of two, and that of degree three, by a factor of three (Stojanovic T. et al., 1996). Tubular inflammation score: Tubular damage was evaluated as non-existent (0), mild (1), moderate (2) and severe (3) as judged in 20 High power Fields (HPF) of cortex and outer stripe of outer medulla. The total tubular damage score was calculated as described for the

total vascular injury score, Interstitial inflammation score: The extent of interstitial infiltration by mononuclear cells was judged as non-existent (0), mild (1), moderate (2) and severe (3) and the total score calculated as described for the total vascular injury score. The number of monocycles/macrophages and T cells within capillary convolutes of glomeruli was calculated as the mean of the respective numbers in all glomeruli in one kidney section.

In situ Hybridisation

Single-stranded RNA probes were generated by *in vitro* transcription of a cDNA clone of rat RANTES (Dr. H Sprenger, Marburg, Germany). *In vitro* transcription was carried out using a Trans-Probe-T kit (Pharmacia, Freiburg, Germany) and digoxigenin-labeled uridine triphosphate (Boehringer, Mannheim, Germany). The vector (pBluescript KS (+) Stratagene, Heidelberg, Germany) was cut with BamHI and transcribed with T3-RNA polymerase to yield antisense probe, to yield sense probe, the plasmid was cut with EcoRI followed by transcription with T7 RNA polymerase. After deparaffinization, kidney sections were digested with 20 µg/ml proteinase K (Boehringer) in PBS for 16 min. Sections were postfixed for 5 min in 4% formaldehyde and acetylated (0.25% acetic anhydride in 0.1 M triethanolamine, 10 min). For *in situ* hybridisation with digoxigenin labelled mRNA, the following hybridisation buffer was used: 5 x standard saline citrate (SSC), 50% formamide, 50 µg/ml tRNA, 50 µg/ml heparin, and 0.1% sodium dodecylsulfate.

After hybridisation at 56°C for 16 h, slides were washed once in 4 x SSC and 2 X SSC for 10 min at 37°C, followed by a washing step in 0.55 x SSC for 30 min and 0.1 SSC at 22°C for 15 min. Antidigoxigenin antibody incubation and alkaline phosphatase reaction was carried out according to guidelines by the manufacturer (Boehringer, Mannheim, Germany), taking nitro-blue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate as colour reagents (Stojanovic T. et al., 1996, Simon M. et al., 1995).

RNase Protection Assay

Total RNA was isolated from whole rat kidney as previously described (Simon M. et al., 1995). RNase protection experiments were performed using a commercial RPA kit (PharMingen, San Diego, California, probe rCK-1). This kit allowed the simultaneous measurement of mRNA species for rat: IL-1α, IL-1β, TNF-α, TNF-β, IL-2, IL-3, IL-4, IL-

5, IL-6, IL-10 and IFN- γ and the housekeeping genes, GAPDH and L32. 20 μ g of total RNA was used for each determination. The protected samples were run out on a precast gel (QuickpointTM Rapid Nucleic Acid Separation System used according to the manufactures recommendations, Novex, San Diego, California). The intensity of the specific bands were
5 quantitated using a Molecular Dynamics Storm 840 Phosphorimager, normalized to L32 gene expression, and averaged over the three animals analysed.

In vitro binding assay

The DMVEC were grown to confluency on coated 96 well flat bottom plates, The resultant endothelial monolayer was either left untreated or treated with various
10 concentrations of IL-1 β (0.1 to 5 ng/ml) for 12 h. The RANTES binding assay was a modification of a previously described procedure (Pattison J. et al., 1994, Wiedermann C.J. et al., 1993). Horseradish, peroxidase (HRP) conjugated anti-human-RANTES monoclonal antibody VL1 (0.1 μ g) was pre-incubated at 25°C for 30 min with an excess of recombinant human RANTES (20 μ g/ml) in DMVEC growth media (without supplements). The
15 chemokine-antibody complex was added then used to assay the relative chemokine binding capacity of the microvascular endothelium. The endothelial monolayer was gently washed 1 x with unsupplemented growth media (25°C) and the chemokine-antibody complex was added and incubated at 25°C for 30 min. The wells were then washed four times with media without sera at 25°C. The HRP reaction was developed for 5 min or less. The optical density
20 at 406 nm of the plate was determined using an ELISA plate reader. The results demonstrate changes in the binding capacity of the inflamed microvascular endothelium for RANTES protein following activation of the endothelial cells. All experiments were performed in quadruplicate and the results displayed are representative of three separate experiments.

Florescence Activated Cell Sorting (FACS) analysis

25 Flow cytometry analysis of dermal microvascular cells (DMVEC) was performed essentially as described (Weber C. et al., 1995). Briefly, confluent DMVEC stimulated with IL-1 β (5 ng/ml), or left untreated for 12 h, were trypsinized, reacted with IL-saturating concentrations of ICAM-1 mAb RR1/1 (kindly provided by Dr. R. Rothlein), E-selectin mAb, VCAM-1 mAb (both Serotec), or isotype control for 30 min on ice, stained with

fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Boehringer Mannheim), and analysed in a FACScan (Becton Dickinson). After correction for unspecific binding, data were expressed as specific mean log fluorescence intensity (sMFI) in channels.

5 *In vitro model system of monocyte recruitment on microvascular endothelium under physiological flow conditions.*

The interaction of monocytes with DMVEC was studied in laminar flow assays performed essentially as described (Weber C. et al., 1997, Kukerti S. et al., 1997, Piali L. et al., 1998). Briefly, DMVEC were grown to confluence in 35 mm Petri dishes, and stimulated with IL-1 β (5 ng/ml) or left untreated for 12 h. The plates were assembled as the lower wall
10 in a parallel wall flow chamber and mounted on the stage of an Olympus IMT-2 inverted microscope with 20x and 40x phase contrast objectives. Monocytes (MonoMac 6 cells) were cultured as reported (Ziegler-Heitbrock H.W.L. et al., 1988, Weber C. et al., 1993) and resuspended at 10⁶/ml in assay buffer (HBSS) containing 10 mM Hepes/pH 7.4 and 0.5% HAS. Shortly before assay, 1 mM Mg²⁺ and 1 mM Ca²⁺ was added. The cell
15 suspensions were kept in a heating block at 37°C during the assay and were perfused into the flow chamber at a rate of 1.5 dyn/cm² for 5 min. For inhibition experiments, monocytes were preincubated with Met-RANTES at different concentrations (0.01 - 1 μ g/ml) for 30 min on ice. The number of firmly adherent cells after 5 min was quantified in multiple fields (at least 5 per experiment) by analysis of images recorded with a long integration JVC
20 3CCD video camera and a JVC SR L 900 E video recorder, and were expressed as cells/mm². The type of adhesion analysed was restricted to primary, i.e. direct interactions of monocytes with endothelium. As an inverse measure of firm arrest, the number of cells rolling at reduced velocity on endothelium was determined within the last 30 sec. of the 5 min intervals, and were assessed as the percentage of all interactions in the field. The number
25 of cells spreading or transmigrating after 5 min intervals was determined in high power fields as described (Luscinskas F.W. et al., 1994), and expressed as percentage of cells firmly attached.

Statistical Analysis

Values are given as mean \pm SEM. Statistical analysis was performed using the

Mann-Whitney U-Wilcoxon rank sum test. A p value < 0.05 was considered as showing a significant difference between two groups.

Results

5 *Allotransplantation of Fisher 344 (F344 RT1^{vi}) kidneys into Lewis (LEW, RT1ⁱ)*

The transplantation of Fisher (344) rat kidneys into Lewis rats in the absence of immunosuppression resulted in a characteristic mononuclear cell infiltrate and tissue damage by day 7 following surgery. Histological examination showed local mononuclear cell infiltration of the intima of preglomerular arteries and tubular interstitium. The major
10 component of this interstitial mononuclear infiltrate consisted of monocyte/macrophage cells. The degree of damage to arteries, arterioles, tubules, and the extent of mononuclear cell infiltration of the interstitium was graded on a scale from non existent (0), mild (1), moderate (2), to severe (3), using a previously described procedure based upon semiquantitative morphometry (see Materials and Methods).

15 The effect of Met-RANTES on this process was examined by treating transplanted animals with daily intravenous injections of Met-RANTES at 200 μ g per animal. The initial injection of Met-RANTES was given within 1 hour following formation of the vascular anastomosis during transplantation surgery. No additional immune suppressive agent was given during the course of the experiment. Light microscopy and immunohistology showed
20 no obvious effect of Met-RANTES treatment on the endogenous kidney.

During organ transplant rejection, the transplanted organ generally increases in weight due to inflammation. The results summarised in Table 1, show that the Met-RANTES treated animals had a statistically significant reduction in transplanted organ weight relative to the untreated animals. The results also suggested a reduction in T cell and
25 monocyte infiltration of glomeruli, however, this reduction was not considered statistically significant (Mann-Whitney U-Wilcoxon rank sum test). The most profound effects of Met-RANTES treatment are summarised in Table 2. The data demonstrate a significant reduction in the vascular injury and tubular rejection score of the Met-RANTES treated animals relative to that seen in the untreated animals. While the general trend regarding interstitial

rejection score showed an apparent reduction in the Met-RANTES treated animals, this could not be considered statistically significant (Mann-Whitney U-Wilcoxon rank sum test).

Histological sections and immunohistochemical stains were examined to evaluate the effects of Met-RANTES on the rejection process. The kidneys were removed seven days following transplantation and prepared as described in Materials and Methods.

Vascular damage with mononuclear cells present within the lumen and the wall of arteries were observed in untreated kidneys. In contrast, Met-RANTES treated animals showed no vascular rejection. The interstitial region of untreated animals demonstrated infiltration of a large number of dark staining mononuclear cells within the interstitium and tubules. By contrast, Met-RANTES treated animals demonstrated reduced mononuclear infiltration, less tubular damage with a well-developed red brush border of proximal tubules.

Localisation of rat RANTES mRNA by in situ hybridisation

Tissue sections taken from rejecting Fisher rat kidneys were used in *in situ* hybridisation studies to demonstrate cell specific expression of RANTES mRNA in the rejecting kidney. The results were similar to those previously described for RANTES expression during rejection of human renal allografts (Pattison J. et al., 1994, Wiedermann C.J. et al., 1993, Von Luetichau I., 1996). Strong expression by infiltrating mononuclear cells and renal tubules and limited but identifiable expression by some endothelial cells was seen.

Met-RANTES treated animals show a reduction in the expression of proinflammatory cytokine mRNA as determined by RNase Protection Assays.

The increased expression of proinflammatory cytokines such as IL-1 α , IL-1 β , IL-2-, IL-3, IL-6, TNF β , TNF α and IFN γ is characteristic of renal transplant rejection (Nickerson P. et al., 1997, Schmouder R.L. et al., 1995, Strom T.B. et al., 1996, Castro M.D. et al., 1998). The expression of these cytokines is an indication of an ongoing inflammatory process. We examined the effect of Met-RANTES on the expression of a series of cytokine in transplanted Fisher rat kidneys using quantitative RNase protection assays. Whole organ RNA samples were isolated from normal control kidneys, untreated transplanted kidneys and Met-RANTES treated transplanted kidneys. The mRNA levels representing the cytokines:

IL-1 α , IL-1 β , TNF β , TNF α , IL-2, IL-3, IL-4, IL-5, IL-6, IL-10 and IFN γ , were determined relative to the internal standards L32 and GAPDH. The results show that seven days following transplantation, the untreated kidneys upregulated mRNAs coding for IL-1 α (24 fold), TNF β (3.2 fold) and IFN γ (1.7) with the most pronounced increase seen in IL-1 β (8.4 fold) and TNF α (4.6 fold). No mRNA expression of IL-2, IL-4, or IL-5 was detected in these kidneys at this time point (7 days post transplantation). The corresponding Met-RANTES treated animals showed a reduced average expression of IL-1 α (25%), IL-1 β (48%), TNF β (34%), TNF α (24%) and IFN γ (24%) relative to the untreated animals.

Transplantation of Brown Norway rat kidneys into Lewis rats: Effect of Met-RANTES in conjunction with low dose cyclosporin A (CyA).

We then expanded the experiments to determine if Met-RANTES could complement low dose CyA treatment in renal transplant rejection. For this procedure, we chose a renal transplant model that would yield a more vigorous rejection episode, namely, the transplantation of Brown Norway kidney into the Lewis rat. A bilateral nephrectomy was performed at the time of transplantation. The level of CyA used, 2.5 mg/kg of body weight administered subcutaneously per day, was previously shown not to significantly block renal rejection in this model (Gröne unpublished results (Stojanovic T. et al., 1996)). Finally, to better detect any synergistic action, a reduced dose of Met-RANTES, 50 μ g per animal per day, was used in these experiments. The results summarised in Table 3 show a statistically significant reduction in the vascular and tubular damage seen in the Met-RANTES/low dose-CyA treated animals as compared to the animals that were only treated with the low dose-CyA. In addition, a significant reduction in mononuclear cell infiltration of the interstitial region was seen. These histological observations were confirmed by functional measurements where serum creatinine was reduced in the Met-RANTES treated animals relative to the untreated controls (0.98 ± 0.12 vs. 1.42 ± 0.17 mg%, (n=3)).

Direct RANTES binding and adhesion molecule expression on activated microvascular endothelium

Since a reduction of monocyte infiltration into vascular luminal spaces represented a prominent feature of Met-RANTES treatment in both transplantation models, we set out to

study potential mechanisms for this effect. In the model of the role of RANTES in renal transplant rejection, it was speculated that RANTES protein, released by activated platelets or secreted by locally inflamed tissue, accumulates on the surface of inflamed endothelium where it may support monocyte recruitment (Nelson P.J. et al., 1998, Pattison J. et al., 1994, Wiedermann C.J. et al., 1993). To study the direct binding of RANTES to microvascular endothelium, we examined the capacity of activated dermal microvascular endothelium (DMVEC) to sequester RANTES protein using a modification of an assay previously employed to detect endothelial surface binding of RANTES in tissue sections (Pattison J. et al., 1994, Wiedermann C.J. et al., 1993). An HRP-conjugated mAb specific for RANTES, VL1, was incubated with an excess of RANTES protein, and the resulting complex was added to resting or IL-1 β -activated microvascular endothelium grown in 96 well flat bottom culture plates. Using an ELISA-like format, the capacity of DMVEC to bind the antigen-mAb complex as opposed to mAb alone was determined. While the microvascular endothelium could bind some RANTES protein without prestimulation, the binding was greatly increased following prestimulation with the proinflammatory cytokine IL-1 α (Figure 1). The background staining of uncomplexed mAb to unstimulated or activated endothelium was negligible.

To further characterise the inflammatory activation of microvascular endothelium, the surface expression of molecules involved in monocyte adhesion, i.e. E-selectin and the Ig superfamily members ICAM-1 and VCAM-1, were determined on DMVEC using a previously established flow cytometry procedure (Weber C. et al., 1995). The analysis revealed that resting DMVEC expressed constitutive surface levels of ICAM-1, however little VCAM-1 or E-selectin was detected (Table 4). Activation of DMVEC with IL-1 for 12 h resulted in an upregulation of ICAM-1 expression and a marked induction of VCAM-1 and E-selectin surface expression (Table 4).

Met-RANTES blocks the firm adhesion of monocytes to inflamed microvascular endothelium but do not effect subsequent events in diapedesis.

In an attempt to gain insight into potential mechanisms of action of Met-RANTES, we studied whether a blockade of RANTES receptors could inhibit the firm arrest and

diapedesis of monocytes on microvascular endothelium. To this end, we used monocytic MonoMac 6 cells that show the adhesive characteristics and integrin repertoire of mature monocytes, and express several chemokine receptors including CCR1 (Erl W. et al., 1995). DMVEC were grown to confluence on Petri dishes which were either left unstimulated or
5 were activated with IL-1 β (5 ng/ml) for 12 h. The microvascular endothelium was then tested in a parallel wall flow chamber where the MonoMac 6 cells were perfused through the chamber at a shear rate of 1.5 dyn/cm² for 5 min. Under such physiological flow conditions, MonoMac 6 cells undergo short periods of rolling, and the attachment of a proportion of cells can be readily converted into shear-resistant arrest. After 5 min of accumulation, the
10 number of MonoMac 6 cells that had undergone firm adhesion to the endothelium was determined (Figure 2 (a)).

Few monocytic cells firmly adhered to unstimulated microvascular endothelium and the pre-exposure of the endothelial cells to RANTES protein showed no significant effect. Prestimulation of the microvascular endothelium with IL-1 β resulted in an increase in shear
15 resistant adhesion of monocytes. Inhibition with mAb confirmed previous findings that this process is mediated by monocyte α 4 and β 2 integrins that interact with ICAM-1 and VCAM-1 expressed on activated endothelium, respectively (Kukerti S. et al., 1997, Lusinskas F.W. et al., 1994). Consistent with the immobilisation of RANTES in direct binding assays, pre-exposure of IL-1 β -activated microvascular endothelium to RANTES
20 protein markedly enhanced the firm arrest and accumulation of monocytes within 5 min (Figure 2 a). Notably, pre-incubation of monocytes with Met-RANTES at various concentrations (0.01 - 1 μ g/ml) completely blocked RANTES-mediated shear resistant adhesion of monocytes on IL-1 β activated DMVEC (Figure 2 a, and data not shown), in parallel, the fraction of monocytes rolling on the activated microvascular endothelium which
25 can be used as an inverse measure of firm arrest, was reduced after preexposure to RANTES, but was restored by Met-RANTES, indicating that the number of initial interactions with the activated endothelium was unaffected. After firm arrest, a fraction of monocytes underwent shape change or spreading, and some ultimately migrated in-between or under endothelial cells. However, RANTES or Met-RANTES did not alter spreading or

TABLES**Table 1**

Fisher and rat kidney transplanted into Lewis rats. The number of monocytes/macrophages and T cells within capillary convolutes of glomeruli was calculated as the mean of the respective numbers in all glomeruli in one kidney section.

	Control (n=9)	Met-RANTES (n=9)
Body Weight (g)	211.8 ± 5.15	195 ± 5.98
Transplant- Kidney Weight	1.41 ± 0.048	1.15 ± 0.08*
Endogenous Kidney Weight	0.91 ± 0.04	0.8 ± 0.04
T Cells in Glomeruli	3.98 ± 0.81	2.75 ± 0.45
Macrophages in Glomeruli	9.16 ± 1.69	5.98 ± 0.87

* Indicates significant ($p < 0.05$) difference between the groups tested.

Table 2
Fisher kidney transplanted into Lewis rats. Summary of histological and immunohistological analysis of the effects of Met-RANTES on vascular damage, and interstitial mononuclear infiltration.

	Vascular Injury		Tubular Damage		Interstitial Inflammation	
	Control	Met-RANTES	Control	Met-RANTES	Control	Met-RANTES
Grade 0	50.67 ± 9.02	85.5 ± 2.66	15.56 ± 6.03	46.00 ± 12.15	1.39 ± 1.11	16.00 ± 7.14
Grade 1	40.44 ± 5.5	12.8 ± 4.17	32.22 ± 8.25	30.00 ± 6.06	44.17 ± 12.39	58.00 ± 8.7
Grade 2	4.44 ± 2.22	0.9 ± 0.6	20.56 ± 5.68	13.00 ± 4.1	18.33 ± 5.95	9.50 ± 4.62
Grade 3	5.55 ± 5.55	0 ± 0.0	31.67 ± 14.19	8.50 ± 7.46	36.11 ± 14.88	10.50 ± 9.44
SCORE	62.67 ± 18.64	16.1 ± 5.2*	33.00 ± 6.44	15.70 ± 5.22	37.78 ± 5.58	24.45 ± 4.62

* Indicates significant ($p < 0.05$) difference between the groups tested.

Table 3

Brown-Norway rat kidneys transplanted into Lewis rats. Summary of histological analysis of the effects of Met-RANTES on vascular and tubular damage, and interstitial mononuclear infiltration in the presence of low dose CyA.

5

SCORE	Cyclosporin 2.5 mg/kg b.w./d	Cyclosporin 2.5 mg/kg b.w./d + Met-RANTES 50 µg/d
VASCULAR INJURY	60.7 ± 1.8	13.7 ± 7.5*
Tubular Damage	124.3 ± 28.7	28.3 ± 14.8*
Interstitial Inflammation	157.3 ± 21.3	71 ± 6.1*

* Indicates significant ($p < 0.05$) difference between the groups tested.

Table 4

Effect of IL-1 β on the surface expression of adhesion molecules in human microvascular endothelial cells. DMVEC were activated with IL-1 β (5 ng/ml) or left untreated (control) for 12 hr., and were reacted with ICAM-1, VCAM-1, E-selectin or isotype control mAbs. The surface protein expression was analysed by FACS in 3 independent experiments and given as specific mean fluorescence intensity (sMFI) after correction for unspecific binding in channels.

15

SMFI (channels)		Control	IL-1 β
ICAM-1	Exp. 1	339	502
	Exp. 2	386	592
	Exp. 3	327	432
VCAM-1	Exp. 1	10	76
	Exp. 2	72	236
	Exp. 3	25	129
E-selectin	Exp. 1	1	120
	Exp. 2	44	265
	Exp. 3	28	177

REFERENCES

- Bishop G.A. et al., *Kidney Int.*, **29**, 708-717, 1986
- Butcher E.C., *Cell*, **67**, 1033-1036, 1991.
- Butcher E.C. et al., *Science*, **272**, 60-66, 1996.
- 5 Castro M.D. et al., *Transpl. Int.*, **11** 1, S15-S18, 1998.
- Devergne O. et al., *J. Exp. Med.*, **179**, 1689-1694, 1994.
- Erl W. et al., *Atherosclerosis*, **113**, 99-107, 1995.
- Fisher B. et al., *Surgery*, **58**, 904-917, 1965.
- Gong J.H. et al., *J. Biol. Chem.*, **271**, 10521-10527, 1996.
- 10 Gröne H.J., *Neph. Dial. Transplant*, **11**, 1916-1917, 1996.
- Kukerti S. et al., *Blood*, **89**, 4104-4111, 1997.
- Lloyd C.M et al., *J. Exp. Med.*, **185**, 1371-1380, 1997.
- Lloyd C.M. et al., *J. Leukoc. Biol.*, **62**, 676-680, 1997.
- Luckas N.W. et al., *J. Leukoc. Biol.*, **59**, 13-17, 1996.
- 15 Luscinskas F.W. et al., *J. Immunol.*, **156**, 326-335, 1994.
- Luster A.D., *N. Engl. J. Med.*, **338**, 436-445, 1998.
- Martindale, The Extra Pharmacopoeia, 31st edition, London, Royal Pharmaceutical Industry, 1996, 557-562.
- Nelson P.J. et al., *Curr. Opin., Immunol.*, **10**, 265-270, 1998.
- 20 Nelson P.J. et al., The Chemokine RANTES. In Cytokines, Handbook of Immunopharmacology Series. R. Thorpe and A. Mire-Sluis, editors. Academic Press. London. 433-448, 1998.
- Nibbs R.J. et al., *J. Biol. Chem.*, **272**, 32078-32083, 1997.
- Nickerson P. et al., *Transplantation*, **27**, 489-494, 1997.
- 25 Pattison J. et al., *Lancet*, **343**, 209-211, 1994.
- Piali L. et al., *Eur. J. Immunol.*, **28**, 961-972, 1998.
- Plater-Zyberk C. et al., *Immunol. Lett.*, **57**, 117-120, 1997.
- Proudfoof A.E. et al., *J. Biol. Chem.*, **271**, 2599-2603, 1996.
- Schlöndorff D. et al., *Kidney Int.*, **51**, 610-621, 1997.
- 30 Schmouder R.L. et al., *Nephrol. Dial. Transplant.*, **10 Suppl 1**, 36-43, 1995.
- Simmons G. et al., *Science*, **276**, 276-279, 1997.

- Simon M. et al., *Am. J. Physio.*, **268**, F240-F250, 1995.
- Springer T.A., *Cell*, **76**, 301-314, 1994.
- Stojanovic T. et al., *Lab. Invest.*, **74**, 496-512, 1996.
- Strom T.B. et al., *Curr. Opin. Immunol.*, **8**, 688-693, 1996.
- 5 Teixeira M.M et al., *J. Clin. Invest.*, **100**, 1657-1666, 1997.
- Valente J.F. et al., *Surg. Clin. North. Am.*, **78**, 1-26, 1998.
- Von Luetichau I., et al., *Cytokine*, **8**, 89-98, 1996.
- Weber C. et al., *Eur. J. Immunol.*, **23**, 852-859, 1993
- Weber C. et al., *J. Immunol.*, **155**, 445-451, 1995.
- 10 Weber C. et al., *J. Clin. Invest.*, **100**, 2085-2093, 1997.
- Wiedermann C.J. et al., *Curr. Biol.*, **3**, 735-739, 1993.
- Ziegler-Heitbrock H.W.L. et al., *Internat. J. Cancer*, **41**, 456-461, 1988.

CLAIMS

1. Use of a chemokine receptor antagonist in combination with a cyclosporin to
produce a pharmaceutical composition for treating or preventing the rejection of
5 transplanted organs, tissues or cells.
2. The use according to claim 1, wherein the chemokine receptor antagonist and the
cyclosporin are used simultaneously, separately or sequentially.
- 10 3. The use according to any preceding claim, wherein the chemokine receptor
antagonist is an amino-terminally truncated chemokine.
4. The use according to claims 1 or 2, wherein the chemokine receptor antagonist is an
amino-terminally extended RANTES.
- 15 5. The use according to claims 1 or 2, wherein the chemokine receptor antagonist is
Met-RANTES.
6. The use according to any preceding claim, wherein the cyclosporin is selected
20 among cyclosporin A as well as metabolites or synthetic analogues thereof.
7. The use according to any preceding claim, wherein the cyclosporin is cyclosporin A.
8. The use according to any preceding claim, for treating or preventing renal allograft
25 transplantation.
9. Pharmaceutical composition containing a chemokine receptor antagonist and a
cyclosporin, in the presence of one or more pharmaceutically acceptable excipients,
for treating or preventing the rejection of transplanted organs, tissues or cells.

10. Pharmaceutical composition containing a chemokine receptor antagonist and a cyclosporin, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential use of its active ingredients in treating or preventing the rejection of transplanted organs, tissues or cells.

5

11. The pharmaceutical composition according to claim 9 or 10, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

10

12. The pharmaceutical composition according to claims 9 or 10, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

13. The pharmaceutical composition according to claims 9 or 10, wherein the chemokine receptor antagonist is Met-RANTES.

15

14. The pharmaceutical composition according to any of claims 9 to 13, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

20

15. The pharmaceutical composition according to any of claims 10 to 14, wherein the cyclosporin is cyclosporin A.

16. The pharmaceutical composition according to any of claims 9 to 15, for treating or preventing renal allograft transplantation.

1/2

IL-1 beta 18 hour stimulation





Figure 1

(a)



(b)




Figure 2

33/05

UNITED STATES OF AMERICA COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION		OFGN FILE NO P/717-189	
As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled: CHEMOKINE RECEPTOR ANTAGONIST AND CYCLOSPORIN IN COMBINED THERAPY			
the specification of which is attached hereto, unless the following box is checked:			
<input type="checkbox"/> was filed on <u>September 16, 1999</u> as United States patent Application Number or PCT International patent application number <u>PCT/EP99/06844</u> and was amended on: _____ (if any).			
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.			
I acknowledge the duty to disclose all information known to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.			
I hereby claim priority benefits under Title 35, United States Code §119 or any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:			
Prior Foreign or Provisional Application(s)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
European	98117697.7	18 September 1998	YES <u>X</u> NO _____
			YES _____ NO _____
I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.			
UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)	
I hereby appoint customer no. 2352 OSTROLENK, FABER, GERB & SOFFEN, LLP, and the members of the firm: Samuel H. Weiner - Reg. No. 18,510; Jerome M. Berliner - Reg. No. 18,653; Robert C. Haber - Reg. No. 24,322; Edward A. Meilman - Reg. No. 24,735; Steven I. Wazburg - Reg. No. 27,409; Max Moskowitz - Reg. No. 30,570; Stephen A. Soffen - Reg. No. 31,063; James A. Funder - Reg. No. 30,173; William O. Gray, III - Reg. No. 30,944; Louis C. Duimich - Reg. No. 30,642; Douglas A. Milro - Reg. No. 31,043; and Michael J. Scheer - Reg. No. 34,425, as attorneys with full power of substitution and revocation to prosecute this application, to transact all business in the Patent & Trademark Office connected therewith and to receive all correspondence.			
SEND CORRESPONDENCE TO:		DIRECT TELEPHONE CALLS TO:	
OSTROLENK, FABER, GERB & SOFFEN, LLP 1180 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036-8403 CUSTOMER NO. 2352		(212) 382 0700	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.			
FULL NAME OF SOLE OR FIRST INVENTOR	INVENTOR'S SIGNATURE	DATE	
Hermann-Joseph GRONE	<i>H. J. Grone</i>	7/5/2001	
RESIDENCE (City and either State or Foreign Country)	COUNTRY OF CITIZENSHIP		
Schillerstrasse 42, D-80336 Munich, Germany DEX	Germany		
POST OFFICE ADDRESS			
Medizinische Poliklinik der Ludwig-Maximilians-Universität München AG Klinische Biochemie, Schillerstrasse 42, D-80336 Munich, Germany			
FULL NAME OF SECOND JOINT INVENTOR (if any)	INVENTOR'S SIGNATURE	DATE	
Peter J. NELSON			
RESIDENCE (City and either State or Foreign Country)	COUNTRY OF CITIZENSHIP		
D-81545 Munich, Germany	U.S.A.		
POST OFFICE ADDRESS			
Harthausenstrasse 70, D-81545 Munich, Germany			

☐ CONTINUED ON PAGE 2

UNITED STATES OF AMERICA COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION		OFGS FILE NO. P/717-189	
<p>As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verify believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled:</p> <p>CHEMOKINE RECEPTOR ANTAGONIST AND CYCLOSPORIN IN COMBINED THERAPY</p>			
the specification of which is attached hereto, unless the following box is checked:			
<input type="checkbox"/> was filed on <u>September 16, 1999</u> as United States patent Application Number or PCT International patent application number <u>PCT/EP99/06844</u> and was amended on _____ (if any)			
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.			
I acknowledge the duty to disclose all information known to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.			
I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:			
Prior Foreign or Provisional Application(s)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
European	98117697.7	18 September 1998	YES <u>X</u> NO _____
			YES _____ NO _____
I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.			
UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)	
I hereby appoint customer no. 2352 OSTROLENK, FABER, GERB & SOFFEN, LLP, and the members of the firm, Samuel H. Weiner - Reg. No. 18,510; Jerome M. Berliner - Reg. No. 18,653; Robert C. Faber - Reg. No. 24,322; Edward A. Meilman - Reg. No. 24,735; Steven I. Weisblud - Reg. No. 27,409; Max Moskowitz - Reg. No. 30,576; Stephen A. Soffen - Reg. No. 31,063; James A. Finder - Reg. No. 30,173; William O. Gray III - Reg. No. 30,944; Louis C. Dujmich - Reg. No. 30,625; Douglas A. Miro - Reg. No. 31,643; and Michael J. Scherz - Reg. No. 34,425, as attorneys with full power of substitution and revocation to prosecute this application, to transact all business in the Patent & Trademark Office connected therewith and to receive all correspondence.			
SEND CORRESPONDENCE TO:		DIRECT TELEPHONE CALLS TO:	
OSTROLENK, FABER, GERB & SOFFEN, LLP 1180 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036-8403 CUSTOMER NO. 2352		(212) 582-0700	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.			
FULL NAME OF SOLE OR FIRST INVENTOR		INVENTOR'S SIGNATURE	DATE
Hermann-Joseph GRONE			
RESIDENCE (City and either State or Foreign Country)		COUNTRY OF CITIZENSHIP	
Schillerstrasse 42, D-80336 Munich, Germany		Germany	
POST OFFICE ADDRESS			
Medizinische Poliklinik der Ludwig-Maximilians-Universitat Munchen AG Klinische Biochemie, Schillerstrasse 42, D-80336 Munich, Germany			
FULL NAME OF SECOND JOINT INVENTOR (IF ANY)		INVENTOR'S SIGNATURE	DATE
Peter J. NELSON			15/05/2001
RESIDENCE (City and either State or Foreign Country)		COUNTRY OF CITIZENSHIP	
D-81545 Munich, Germany DEX		U.S.A.	
POST OFFICE ADDRESS			
Harthausenstrasse 70, D-81545 Munich, Germany			

☐ CONTINUED ON PAGE 2

UNITED STATES OF AMERICA COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION		OFGS FILE NO. P/717-189																																					
<p>As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled:</p> <p>CHEMOKINE RECEPTOR ANTAGONIST AND CYCLOSPORIN IN COMBINED THERAPY</p>																																							
<p>the specification of which is attached hereto, unless the following box is checked:</p> <p><input type="checkbox"/> was filed on <u>September 16, 1999</u> as United States patent Application Number or PCT International patent application number <u>PCT/EP99/06844</u> and was amended on _____ (if any).</p> <p>I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.</p> <p>I acknowledge the duty to disclose all information known to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.</p> <p>I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:</p> <p>Prior Foreign or Provisional Application(s)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">COUNTRY</th> <th style="width: 25%;">APPLICATION NUMBER</th> <th style="width: 25%;">DATE OF FILING (day, month, year)</th> <th style="width: 25%;">PRIORITY CLAIMED UNDER 35 U.S.C. 119</th> </tr> </thead> <tbody> <tr> <td>European</td> <td>98117697.7</td> <td>18 September 1998</td> <td>YES <u>X</u> NO _____</td> </tr> <tr> <td></td> <td></td> <td></td> <td>YES _____ NO _____</td> </tr> </tbody> </table> <p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 33%;">UNITED STATES APPLICATION NUMBER</th> <th style="width: 33%;">DATE OF FILING (day, month, year)</th> <th style="width: 34%;">STATUS (patented, pending, abandoned)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>I hereby appoint customer no. 2352 OSTROLENK, FABER, GERB & SOFFEN, LLP, and the members of the firm, Samuel H. Weiner - Reg. No. 18,510; Jerome M. Berliner - Reg. No. 18,653; Robert C. Faber - Reg. No. 24,322; Edward A. Meilman - Reg. No. 24,735; Steven I. Weisburd - Reg. No. 27,409; Max Moskowitz - Reg. No. 30,576; Stephen A. Soffen - Reg. No. 31,063; James A. Finder - Reg. No. 30,173; William O. Gray, III - Reg. No. 30,944; Louis C. Dymnich - Reg. No. 30,625; Douglas A. Miro - Reg. No. 31,643, and Michael J. Scherer - Reg. No. 34,425, as attorneys with full power of substitution and revocation to prosecute this application, to transact all business in the Patent & Trademark Office connected therewith and to receive all correspondence.</p> <p>SEND CORRESPONDENCE TO: OSTROLENK, FABER, GERB & SOFFEN, LLP 1180 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036-8403 CUSTOMER NO. 2352</p> <p>DIRECT TELEPHONE CALLS TO (212) 382-0700</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">FULL NAME OF SOLE OR FIRST INVENTOR Hermann-Joseph GRONE</td> <td style="width: 30%;">INVENTOR'S SIGNATURE</td> <td style="width: 30%;">DATE</td> </tr> <tr> <td colspan="2">RESIDENCE (City and either State or Foreign Country) Schillerstrasse 42, D-80336 Munich, Germany</td> <td>COUNTRY OF CITIZENSHIP Germany</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS Medizinische Poliklinik der Ludwig-Maximilians-Universitat Munchen AG Klinische Biochemie, Schillerstrasse 42, D-80336 Munich, Germany</td> </tr> <tr> <td>FULL NAME OF SECOND JOINT INVENTOR (if any) Peter J. NELSON</td> <td>INVENTOR'S SIGNATURE</td> <td>DATE</td> </tr> <tr> <td colspan="2">RESIDENCE (City and either State or Foreign Country) D-81545 Munich, Germany</td> <td>COUNTRY OF CITIZENSHIP U.S.A.</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS Harthausenstrasse 70, D-81545 Munich, Germany</td> </tr> </table>				COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119	European	98117697.7	18 September 1998	YES <u>X</u> NO _____				YES _____ NO _____	UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)				FULL NAME OF SOLE OR FIRST INVENTOR Hermann-Joseph GRONE	INVENTOR'S SIGNATURE	DATE	RESIDENCE (City and either State or Foreign Country) Schillerstrasse 42, D-80336 Munich, Germany		COUNTRY OF CITIZENSHIP Germany	POST OFFICE ADDRESS Medizinische Poliklinik der Ludwig-Maximilians-Universitat Munchen AG Klinische Biochemie, Schillerstrasse 42, D-80336 Munich, Germany			FULL NAME OF SECOND JOINT INVENTOR (if any) Peter J. NELSON	INVENTOR'S SIGNATURE	DATE	RESIDENCE (City and either State or Foreign Country) D-81545 Munich, Germany		COUNTRY OF CITIZENSHIP U.S.A.	POST OFFICE ADDRESS Harthausenstrasse 70, D-81545 Munich, Germany		
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119																																				
European	98117697.7	18 September 1998	YES <u>X</u> NO _____																																				
			YES _____ NO _____																																				
UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)																																					
FULL NAME OF SOLE OR FIRST INVENTOR Hermann-Joseph GRONE	INVENTOR'S SIGNATURE	DATE																																					
RESIDENCE (City and either State or Foreign Country) Schillerstrasse 42, D-80336 Munich, Germany		COUNTRY OF CITIZENSHIP Germany																																					
POST OFFICE ADDRESS Medizinische Poliklinik der Ludwig-Maximilians-Universitat Munchen AG Klinische Biochemie, Schillerstrasse 42, D-80336 Munich, Germany																																							
FULL NAME OF SECOND JOINT INVENTOR (if any) Peter J. NELSON	INVENTOR'S SIGNATURE	DATE																																					
RESIDENCE (City and either State or Foreign Country) D-81545 Munich, Germany		COUNTRY OF CITIZENSHIP U.S.A.																																					
POST OFFICE ADDRESS Harthausenstrasse 70, D-81545 Munich, Germany																																							

☐ CONTINUED ON PAGE 2

